DTX3L was originally identified as a binding partner of BAL1 (PARP9/ARTD9), which is an oncogenic factor in DLBCL with a prominent immune/inflammatory infiltrate (Juszczynski et al., 2006). The gene discussed is PARP9; the disease is diffuse large B-cell lymphoma.